Table 2 Distribution and comparison of disease characteristics according to groups
From: Splinting in carpal tunnel syndrome—should we use it during the daytime?
Group 1 n (wrists) = 20 Median (IQR 25–75%), n (%) | Group 2 n (wrists) = 28 Median (IQR 25–75%), n (%) | Group 3 n (wrists) = 22 Median (IQR 25–75%), n (%) | *p | |
|---|---|---|---|---|
Symptom duration (months) | 21.0 (12.0–60.0) | 28.0 (12.0–72.0)a | 24.0 (10.50–72.0)a | 0.736 |
The most prominent symptom | ||||
Pain | 4 (20) | 5 (17.8) | 8 (36.4) | 0.068 |
Numbness | 14 (70) | 15 (53.6) | 14 (63.6) | |
Tingling | 0 | 8 (28.6) | 0 | |
Weakness | 2 (10) | 0 | 0 | |
Nocturnal symptoms | 15 (75) | 24 (85.7) | 22 (100) | 0.054 |
Nocturnal symptom duration (months) | 4.0 (1.50–12.0) | 5.0 (1.0–14.0)a | 5.5 (3.0–12.0)a | 0.721 |
Tinnel’s test positivity | 8 (40) | 13 (46.4) | 10 (45.5) | 0.900 |
Phalen’s test positivity | 15 (75) | 20 (71.4) | 15 (68.2) | 0.889 |
CTS severity | ||||
Mild | 8 (40) | 16 (57.1) | 8 (36.4) | 0.290 |
Moderate | 12 (60) | 12 (42.9) | 14 (63.6) | |